No Data
No Data
Allogene Therapeutics Files For Offering Of Up To 37.93M Shares Of Common Stock
Allogene Therapeutics Files For Offering Of Up To 37.93M Shares Of Common Stock
Analysts Offer Insights on Healthcare Companies: Allogene Therapeutics (ALLO) and Generation Bio (GBIO)
B. Riley Adjusts Price Target on Allogene Therapeutics to $7 From $10, Keeps Buy Rating
Allogene Therapeutics (ALLO) has an average rating of outperform and price targets ranging from $4.40 to $17, according to analysts polled by Capital IQ. Price: 3.0548, Change: +0.15, Percent Change:
Stifel Maintains Hold on Allogene Therapeutics, Raises Price Target to $4.6
Stifel analyst Benjamin Burnett maintains Allogene Therapeutics (NASDAQ:ALLO) with a Hold and raises the price target from $4.4 to $4.6.
Allogene Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/14/2024 50.33% Stifel $4.4 → $4.6 Maintains Hold 03/19/2024 226.8% HC Wainwright & Co. → $10 Reiterates
Earnings Call Summary | Allogene Therapeutics(ALLO.US) Q1 2024 Earnings Conference
The following is a summary of the Allogene Therapeutics, Inc. (ALLO) Q1 2024 Earnings Call Transcript:Financial Performance:Allogene Therapeutics reported a Q1 2024 cash balance of $397.3 million.The